[Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?]

Area of Science:

• Cardiology
• Preventive Medicine
• Public Health

Background:

• Cardiovascular disease (CVD) primary prevention relies on managing individual risk factors.
• Statin eligibility is determined by estimated CVD risk and LDL-cholesterol levels.
• Commonly used risk scores include PROCAM, Framingham, and the European score.

Purpose of the Study:

• To compare different cardiovascular disease risk scores.
• To discuss the practical application of these scores for statin prescription in primary prevention.
• To analyze the consequences and benefits of applying these scores in Switzerland.

Main Methods:

• Review and comparison of existing cardiovascular disease risk assessment scores (PROCAM, Framingham, European).
• Discussion of their practical implications for statin therapy initiation.
• Analysis of the Swiss context, including GSLA recommendations and survey data on score usage.

Main Results:

• The PROCAM score, adjusted for Swiss risk levels, is recommended by the Swiss Group Lipids and Atherosclerosis (GSLA).
• A survey indicates PROCAM is the most frequently used risk score in Switzerland.
• Differences in score methodologies impact risk stratification and subsequent treatment decisions.

Conclusions:

• Understanding the nuances between risk scores is crucial for accurate statin prescription in primary prevention.
• The adoption of the adjusted PROCAM score in Switzerland aligns with national recommendations.
• Implementing appropriate risk assessment tools can optimize cardiovascular disease prevention strategies.